Rapid Magnetic Blood Filtration for the Treatment of Sepsis a Feasibility Study
This project will look at a novel method of treating sepsis, one of the world’s leading causes of death. The method uses magnetic nanoparticles (MNPs) that bind to specific entities in blood, combined with MediSieve's patented mag...
This project will look at a novel method of treating sepsis, one of the world’s leading causes of death. The method uses magnetic nanoparticles (MNPs) that bind to specific entities in blood, combined with MediSieve's patented magnetic blood filter. By infusing the MNPs into an extra-corporeal blood loop containing the filter, MediSieve can remove both the pathogens that cause sepsis (bacteria) and the endotoxins that are responsible for the dysregulated immune response which is characteristic of sepsis. Importantly the method would work even in antibiotic resistant cases.
Annually, there are 1M cases in the US and 900K in Europe, with 135K deaths/year in the EU. Mortality rates are 29-50% with a cost of €25K per patient. With the aging of global populations sepsis incidence is increasing rapidly (8-13% annually in the decade to 2013).
The challenge is that both the pathogens and the immune response contribute to the disease. The destruction of bacteria by the immune system or antibiotics creates large quantities of endotoxins, which in turn aggravate the immune response and cause a cascade towards septic shock. MNPs that bind specifically to gram-negative bacteria and endotoxins enable the two targets to be rapidly and safely removed from circulation using MediSieve’s magnetic filter. The method provides the unique capability to specifically target both root causes of sepsis, reduce both the mortality and the economic costs of sepsis.
The objectives of this Phase 1 study are to validate the technical and commercial feasibility of the proposed treatment method. The latter includes detailed market research, business planning, healthcare economics modelling and a detailed investment proposal with timelines and return on investment projections. The technical assessment will include in vitro lab studies validating that the MNPs efficiently bind to both targets and captured by the magnetic filter. A Phase 2 project would include pre-clinical and clinical studies.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.